PCN94 - The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma (INHL) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Colombia

Saved in:
Bibliographic Details
Published inValue in health Vol. 16; no. 7; p. A408
Main Authors Bertwistle, D., Munakata, J., Wehler, E, Leyva, V., Ariza, J.G., Zambrano, C., Gonzalez, L.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.11.2013
Online AccessGet full text

Cover

More Information
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2013.08.492